Abstract
Interstitial lung diseases in general, and idiopathic pulmonary fibrosis in particular, are complex disorders with multiple pathogenetic pathways, various disease behaviour profiles and different responses to treatment, all facets that make personalised medicine a highly attractive concept. Personalised medicine is aimed at describing distinct disease subsets taking into account individual lifestyle, environmental exposures, genetic profiles and molecular pathways. The cornerstone of personalised medicine is the identification of biomarkers that can be used to inform diagnosis, prognosis and treatment stratification. At present, no data exist validating a personalised approach in individual diseases. However, the importance of the goal amply justifies the characterisation of genotype and pathway signatures with a view to refining prognostic evaluation and trial design, with the ultimate aim of selecting treatments according to profiles in individual patients.
Abstract
Personalised medicine provides a potential road map for guiding clinical care in interstitial lung diseases http://ow.ly/xZop30iQOoQ
Footnotes
Number 6 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche
Previous articles in this series: No. 1: Chung KF. Personalised medicine in asthma: time for action. Eur Respir Rev 2017; 26: 170064. No. 2: Bonsignore MR, Suarez Giron MC, Marrone O, et al. Personalised medicine in sleep respiratory disorders: focus on obstructive sleep apnoea diagnosis and treatment. Eur Respir Rev 2017; 26: 170069. No. 3: Mascaux C, Tomasini P, Greillier L, et al. Personalised medicine for nonsmall cell lung cancer. Eur Respir Rev 2017; 26: 170066. No. 4: Noell G, Faner R, Agusti A. From systems biology to P4 medicine: applications in respiratory medicine. Eur Respir Rev 2018; 27: 170110. No. 5: Wouters EFM, Wouters BBREF, Augustin IL, et al. Personalised pulmonary rehabilitation in COPD. Eur Respir Rev 2018; 27: 170125.
Conflict of interest: A.U. Wells reports personal fees from InterMune/Roche and Boehringer Ingelheim, outside the submitted work.
Provenance: Commissioned article, peer reviewed.
- Received October 15, 2017.
- Accepted March 5, 2018.
- Copyright ©ERS 2018.
ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.